Reduced-intensity allogeneic transplantation for myeloma: reality bites.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.Bone marrow transplantation · 2016
   Trial
2. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010
   Trial
3. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.American journal of hematology · 2024
   Review
4. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.American journal of hematology · 2022
   Article
5. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementAmerican journal of hematology · 2018
   Article
6. Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.Blood advances · 2017
   Article
7. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
   Article
8. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?Current hematologic malignancy reports · 2017
   Review
9. Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.Frontiers in oncology · 2017
   Review
10. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.American journal of hematology · 2016
    Review
11. Myeloma today: Disease definitions and treatment advances.American journal of hematology · 2016
    Review
12. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?Current hematologic malignancy reports · 2013
    Review
13. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.American journal of hematology · 2012
    Article
14. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.The Clinical biochemist. Reviews · 2009
    Article

Corrections and comments

• Comment on
  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.2009
• Comment on
  Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.